Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: March 26, 2023

Details for Patent: 8,479,730

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,479,730
Title:Inhaler device
Abstract: An inhaler device (1) for powdered medicaments. The device (1) has a body (5) that has a recess (50) for holding a capsule containing a powdered medicament to be inhaled, at least one air passage (90) that is tangentially disposed to the recess (50) , and a mouthpiece (30) that includes a coaxially disposed inhalation passage (70) that communicates with the recess (50) of the body (5). The body (5) has a pair of opposed spring (105) biased push-buttons (40) that each include at least one piercing element (95) for piercing the capsule when loaded in the recess (50). The medicament is released from the pierced capsule when air is drawn through the air passage(s) (90) into the recess (50) and swirled about therein. The mouthpiece (30) is pivotally attached to the edge of the body (5) so that it is pivotable between an open loading position and a closed dispensing position about an axis that is perpendicular to the longitudinal axis of the inhaler (1).
Inventor(s): Ziegler; Dominik (Basel, CH), Smetham; Grant (Cambridge, GB), Citterio; Mauro (Osnago, IT)
Assignee: Novartis AG (Basil, CH)
Application Number:11/568,466
Patent Claim Types:
see list of patent claims
Dosage form; Delivery; Device; Compound;

Drugs Protected by US Patent 8,479,730

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis ARCAPTA NEOHALER indacaterol maleate POWDER;INHALATION 022383-001 Jul 1, 2011 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis UTIBRON glycopyrrolate; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,479,730

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0410712.4May 13, 2004
PCT Information
PCT FiledMay 12, 2005PCT Application Number:PCT/EP2005/005182
PCT Publication Date:December 01, 2005PCT Publication Number: WO2005/113042

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.